Cardioprotection: SGLT2 blockers in T2DM

Comment

Caroline Barranco. Nat Rev Cardiol. 2018 May.

. 2018 May;15(5):255.

doi: 10.1038/nrcardio.2018.35. Epub 2018 Mar 29.

No abstract available

Comment on

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
Rådholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR, Neal B. Rådholm K, et al. Circulation. 2018 Jul 31;138(5):458-468. doi: 10.1161/CIRCULATIONAHA.118.034222. Circulation. 2018. PMID: 29526832 Free PMC article. Clinical Trial.
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh SY, Thuresson M, Chen H, Surmont F, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. Kosiborod M, et al. J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639. doi: 10.1016/j.jacc.2018.03.009. Epub 2018 Mar 11. J Am Coll Cardiol. 2018. PMID: 29540325 Clinical Trial.